SavedAdd your journal

Journals / Experimed / 2026 / Volume: 13 Issue: 2

Cryptotanshinone Protects Against Acute Pulmonary Edema

Ümit Yılmaz(Karabuk University, Faculty of Medicine, Department of Physiology)0000-0003-0248-3483
Mehmet Demir(Karabuk University, Faculty of Medicine, Department of Physiology)0000-0001-6990-3337
Journal
Experimed
Pages
—
Publication Date
2023-09-18
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: CTS showed a protective effect against acute pulmonary edema, which indicates that it may be used as a new therapeutic agent against pulmonary toxicity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Cryptotanshinone (CTS) is a compound with anti-inflammatory, anti-bacterial, anti-oxidative and anti-aggregant functions.
📊
Key Findings & Data:Materials and Methods: In this study, 4 groups (control, sham, ANTU and ANTU+CTS) were established from a total of 40 rats.
💡
Conclusion & Impact:Conclusion: CTS showed a protective effect against acute pulmonary edema, which indicates that it may be used as a new therapeutic agent against pulmonary toxicity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Cryptotanshinone · α-naphthylthiourea · pulmonary edema

Abstract

Objective: Cryptotanshinone (CTS) is a compound with anti-inflammatory, anti-bacterial, anti-oxidative and anti-aggregant functions. We aimed to determine the effects of CTS on α-naphtilthiourea (ANTU)-induced acute pulmonary edema. Materials and Methods: In this study, 4 groups (control, sham, ANTU and ANTU+CTS) were established from a total of 40 rats. The ANTU+CTS group received intraperitoneal CTS for seven days, and both ANTU and ANTU+CTS received an ANTU administration for the induction of peripheral effusion. Four hours after the ANTU administration, the rats were subjected to a forced swim test and were decapitated. Swimming times of rats, amount of pleural effusion (PE), lung weight (LW)/body weight (BW), and PE/BW ratios were determined. Results: At the end of the experiment, PE was not detected in the lungs of control and sham group rats. It was determined that the PE, LW/ BW and PE/BW decreased statistically, while swimming time increased after acute pulmonary edema in the CTS group (p<0.05). Conclusion: CTS showed a protective effect against acute pulmonary edema, which indicates that it may be used as a new therapeutic agent against pulmonary toxicity.

🔖

Cite This Article

Yılmaz, Ü., Demir, M. (2023). Cryptotanshinone Protects Against Acute Pulmonary Edema. Experimed, Volume: 13 Issue: 2. https://doi.org/10.26650/experimed.1308908

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (40)

  1. Panjwani A, Salman MR. An uncommon cause of pleural effusion. Breathe (Sheff) 2019; 15(2): e84-e9. google scholar
  2. Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest 1993; 104(5): 1486-9. google scholar
  3. Riedel M. Noncardiogenic pulmonary edema. Ceskoslovenska fysiologie 1996; 45(2): 112-9. google scholar
  4. MacIver DH, Clark AL. The vital role of the right ventricle in the pathogenesis of acute pulmonary edema. Am J Cardiol 2015; 115(7): 992-1000. google scholar
  5. Glaus T, Schellenberg S, Lang J. Cardiogenic and non cardiogenic pulmonary edema: pathomechanisms and causes. Schweiz Arch Tierheilkd 2010; 152(7): 311-7. google scholar
  6. Rapin M, Lemaire F. Les oedemes pulmonaires non hemodynamiques [Non cardiogenic pulmonary edema]. Sem Hop 1979; 55(7-8): 331-4. google scholar
  7. Alwi I. Diagnosis and management of cardiogenic pulmonary edema. Acta Med Indones 2010; 42(3): 176-84. google scholar
  8. Wang Y-J, Liao C-Y, Kao C-W. Nursing assessment and management of patients with cardiogenic pulmonary edema. Hu Li Za Zhi 2012; 59(1): 24. google scholar
  9. Yu XY, Lin SG, Chen X, Zhou ZW, Liang J, Duan W, et al. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer’s disease, across the blood-brain barrier. Curr Drug Metab 2007; 8(4): 365-78. google scholar
  10. Kim SY, Moon TC, Chang HW, Son KH, Kang SS, Kim HP. Effects of tanshinone I isolated from Salvia miltiorrhiza bunge on arachidonic acid metabolism and in vivo inflammatory responses. Phytother Res 2002; 16(7): 616-20. google scholar
  11. Park IJ, Kim MJ, Park OJ, Park MG, Choe W, Kang I, et al. Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas(APO1/CD95)-mediated apoptosis through Bcl-2 and MAPK regulation. Cancer Lett 2010; 298(1): 88-98. google scholar
  12. Lee WY, Liu KW, Yeung JH. Reactive oxygen species-mediated kinase activation by dihydrotanshinone in tanshinones-induced apoptosis in HepG2 cells. Cancer Lett 2009; 285(1): 46-57. google scholar
  13. Jin DZ, Yin LL, Ji XQ, Zhu XZ. Cryptotanshinone inhibits cyclooxygenase-2 enzyme activity but not its expression. Eur J Pharmacol 2006; 549(1-3): 166-72. google scholar
  14. Chen Q, Zhuang Q, Mao W, Xu XM, Wang LH, Wang HB. Inhibitory effect of cryptotanshinone on angiogenesis and Wnt/beta-catenin signaling pathway in human umbilical vein endothelial cells. Chin J Integr Med 2014; 20(10): 743-50. google scholar
  15. Tang S, Shen XY, Huang HQ, Xu SW, Yu Y, Zhou CH, et al. Cryptotanshinone suppressed inflammatory cytokines secretion in RAW264.7 macrophages through inhibition of the NF-kappaB and MAPK signaling pathways. Inflammation 2011; 34(2): 111-8. google scholar
  16. Zhang Q, Gan C, Liu H, Wang L, Li Y, Tan Z, et al. Cryptotanshinone reverses the epithelial-mesenchymal transformation process and attenuates bleomycin-induced pulmonary fibrosis. Phytother Res 2020; 34(10): 2685-96. google scholar
  17. Zhang Y, Lu W, Zhang X, Lu J, Xu S, Chen S, et al. Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacol Res 2019; 147: 104307. google scholar
  18. Wang X, Wan W, Lu J, Zhang Y, Quan G, Pan X, et al. Inhalable cryptotanshinone spray-dried swellable microparticles for pulmonary fibrosis therapy by regulating TGF-beta1/Smad3, STAT3 and SIRT3 pathways. Eur J Pharm Biopharm 2022; 172: 177-92. google scholar
  19. Tang Y, Chen Y, Chu Z, Yan B, Xu L. Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 2014; 723: 494-500. google scholar
  20. Jiang Y, You F, Zhu J, Zheng C, Yan R, Zeng J. Cryptotanshinone Ameliorates Radiation-Induced Lung Injury in Rats. Evid Based Complement Alternat Med 2019; 2019: 1908416. google scholar
  21. Markov AK, Causey AL, Didlake RH, Lemos LB. Prevention of alpha-naphthylthiourea-induced pulmonary edema with fructose-1,6-diphosphate. Exp Lung Res 2002; 28(4): 285-99. google scholar
  22. Richter CP. The physiology and cytology of pulmonary edema and pleural effusion produced in rats by alpha-naphthyl thiourea (ANTU). J Thoracic Surg 1952; 23(1): 66-91. google scholar
  23. Park OK, Choi JH, Park JH, Kim IH, Yan BC, Ahn JH, et al. Comparison of neuroprotective effects of five major lipophilic diterpenoids from Danshen extract against experimentally induced transient cerebral ischemic damage. Fitoterapia 2012; 83(8): 1666-74. google scholar
  24. De Caro C, Raucci F, Saviano A, Cristiano C, Casillo GM, Di Lorenzo R, et al. Pharmacological and molecular docking assessment of cryptotanshinone as natural-derived analgesic compound. Biomed Pharmacother 2020; 126: 110042. google scholar
  25. Bai T, Yang K, Qin C, Xu T, Yu X, Zhang J. Cryptotanshinone ameliorates renal ischaemia-reperfusion injury by inhibiting apoptosis and inflammatory response. Basic Clin Pharmacol Toxicol 2019; 125(5): 420-9. google scholar
  26. Slattery DA, Cryan JF. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc 2012; 7(6): 1009-14. google scholar
  27. Barton CC, Bucci TJ, Lomax LG, Warbritton AG, Mehendale HM. Stimulated pulmonary cell hyperplasia underlies resistance to alpha-naphthylthiourea. Toxicology 2000; 143(2): 167-81. google scholar
  28. Zhang J, Huang M, Guan S, Bi HC, Pan Y, Duan W, et al. A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. J Pharmacol Exp Ther 2006; 317(3): 1285-94. google scholar
  29. Chen L, Wang HJ, Xie W, YaoY, Zhang YS, Wang H. Cryptotanshinone inhibits lung tumorigenesis and induces apoptosis in cancer cells in vitro and in vivo. Mol Med Rep 2014; 9(6): 2447-52. google scholar
  30. Qi PF, Li YL, Liu XM, Jafari FA, Zhang XJ, Sung QL, et al. Cryptotanshinone suppresses non-small cell lung cancer via microRNA-146a-5p/EGFR axis. Int J Biol Sci 2019; 15(5): 1072-9. google scholar
  31. Wang H, Zhang Y, Zhang Y, Liu W, Wang J. Cryptotanshinone inhibits lung cancer invasion via microRNA-133a/matrix metalloproteinase 14 regulation. Oncol Lett 2019; 18(3): 2554-9. google scholar
  32. Cao L, Hong WP, Cai PH, Xu CC, Bai XP, Zhao ZX, et al. Cryptotanshinone strengthens the effect of gefitinib against non-small cell lung cancer through inhibiting transketolase. Eur J Pharmacol 2021; 890: 173647. google scholar
  33. Li J, Zheng M, Wang C, Jiang J, Xu C, Li L, et al. Cryptotanshinone attenuates allergic airway inflammation through negative regulation of NF-kappaB and p38 MAPK. Biosci Biotechnol Biochem 2020; 84(2): 268-78. google scholar
  34. Wang C, Zheng M, Choi Y, Jiang J, Li L, Li J, et al. Cryptotanshinone attenuates airway remodeling by inhibiting crosstalk between tumor necrosis factor-like weak inducer of apoptosis and transforming growth factor beta 1 signaling pathways in asthma. Front Pharmacol 2019; 10: 1338. google scholar
  35. Jeon SJ, Son KH, Kim YS, Choi YH, Kim HP. Inhibition of prostaglandin and nitric oxide production in lipopolysaccharide-treated RAW 264.7 cells by tanshinones from the roots of Salvia miltiorrhiza bunge. Arch Pharm Res 2008; 31(6): 758-63. google scholar
  36. Tang Y, Chen YL, Chu Z, Yan B, Xu LJ. Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice. Eur J Pharmacol 2014; 723: 494-500. google scholar
  37. Zhang YT, Lu WT, Zhang XL, Lu J, Xu SW, Chen SR, et al. Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacol Res 2019; 147:104307. google scholar
  38. Jiang YF, You FM, Zhu J, Zheng C, Yan R, Zeng JH. Cryptotanshinone ameliorates radiation-induced lung injury in rats. Evid Based Complement Alternat Med 2019; 2019: 1908416. google scholar
  39. Wang XH, Wan W, Lu J, Zhang YT, Quan GL, Pan X, et al. Inhalable cryptotanshinone spray-dried swellable microparticles for pulmonary fibrosis therapy by regulating TGF-beta 1/Smad3, STAT3 and SIRT3 pathways. Eur J Pharm Biopharm 2022; 172: 177-92. google scholar
  40. Zhang YT, Lu WT, Zhang XL, Lu J, Xu SW, Chen SR, et al. Cryptotanshinone protects against pulmonary fibrosis through inhibiting Smad and STAT3 signaling pathways. Pharmacol Res 2019; 147:104307. google scholar